Cardiovascular

• Clinical Data

BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival

pharminent May 12, 2026

• Regulatory

Bayer plans filings for cardiac amyloidosis imaging agent

pharminent May 7, 2026

• Clinical Data

Cytokinetics heart drug scores in closely watched trial

pharminent May 5, 2026

• Commercial

Pfizer protects $6.4bn heart disease blockbuster from generics, for now

pharminent April 29, 2026

• Commercial

Novartis shares fall as Entresto sales weaken

pharminent April 28, 2026

• Policy / Pricing

J&J puts blockbuster blood thinner Xarelto on TrumpRx

pharminent April 27, 2026

• Clinical Data

Cardiometabolic trials: Using expertise to turn complexity into robust results

pharminent April 24, 2026

• Regulatory

Bayer wins MHRA approval for Kerendia in heart failure

pharminent April 13, 2026

• Clinical Data

ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH

pharminent April 2, 2026

• Clinical Data

ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D

pharminent April 1, 2026

• Clinical Data

ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose

pharminent April 1, 2026

• Clinical Data

ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit

pharminent April 1, 2026

• Clinical Data

Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout

pharminent March 30, 2026

• Other

One in four diabetics has undiagnosed heart failure; study

pharminent March 30, 2026

• M&A / Deals

Immutrin raises $87M to advance drug for progressive heart disease

pharminent March 24, 2026